{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:52:22Z","timestamp":1789087942112,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Akcea Therapeutics"},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIMED at Karolinska Institutet"},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Hypertriglyceridaemia (hTG) is associated with atherosclerotic cardiovascular disease, pancreatitis, and non-alcoholic fatty liver disease (NAFLD) in large population-based studies. The understanding of the impact of hereditary hTG and cardiometabolic disease status on the development of hTG and its associated cardiometabolic outcomes is more limited. We aimed to establish a multigenerational cohort to enable studies of the relationship between hTG, cardiometabolic disease and hereditary factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The population-based observational Stockholm hyperTRIglyceridaemia REGister (STRIREG) study includes 1 460 184 index individuals who have measured plasma triglycerides in the clinical routine in Region Stockholm, Sweden, between 1 January 2000 and 31 December 2021. The laboratory measurements also included basic haematology, blood lipid panel, liver function tests, and HbA1c. Using the Swedish Multi-Generation register, 2 147 635 parents and siblings to the indexes were identified to form the complete study cohort. Laboratory data from participants were combined with data from several national registers that provided information on the cause of death, medical diagnoses, dispensed medicines, and socioeconomic factors including country of birth, education level, and marital status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The multi-generational longitudinal STRIREG cohort provides a unique opportunity to investigate different aspects of hTG as well as heredity for other metabolic diseases. Important outcome measures include mortality, cardiovascular mortality, major cardiovascular events, development of incident diabetes, and NAFLD. The STRIREG study will provide a deeper understanding of the impact of hereditary factors and associated cardiometabolic complications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjopen\/oeae010","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T21:45:32Z","timestamp":1708379132000},"source":"Crossref","is-referenced-by-count":4,"title":["Relation among hypertriglyceridaemia, cardiometabolic disease, and hereditary factors\u2014design and rationale of the Stockholm hyperTRIglyceridaemia REGister study"],"prefix":"10.1093","volume":"4","author":[{"given":"Daniel P","family":"Andersson","sequence":"first","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet, Cardio Metabolic Unit, C2:94, Karolinska University Hospital Huddinge, 141 86 Stockholm , Sweden"},{"name":"Medical Unit Endocrinology, C2:94, Karolinska University Hospital Huddinge , 141 86 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-9369","authenticated-orcid":false,"given":"Karin","family":"Littmann","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet, Cardio Metabolic Unit, C2:94, Karolinska University Hospital Huddinge, 141 86 Stockholm , Sweden"},{"name":"Medical Unit Endocrinology, C2:94, Karolinska University Hospital Huddinge , 141 86 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Kindborg","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet, Cardio Metabolic Unit, C2:94, Karolinska University Hospital Huddinge, 141 86 Stockholm , Sweden"},{"name":"Medical Unit Endocrinology, C2:94, Karolinska University Hospital Huddinge , 141 86 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eklund","sequence":"additional","affiliation":[{"name":"Medical Unit Clinical Chemistry, C1-62, Karolinska University Laboratory, 141 86 \u00a0 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Sejersen","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Clinical Chemistry, Uppsala University, Uppsala University Hospital, 751 85 Uppsala , Sweden"},{"name":"Unilabs AB , Unilabs Laboratory Medicine Stockholm, Section of Clinical Chemistry, 171 54 Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Yan","sequence":"additional","affiliation":[{"name":"Institute of Environmental Medicine, Unit of Biostatistics, Karolinska Institutet, Nobels v\u00e4g 13, 17 177 \u00a0 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eriksson Hogling","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet, Cardio Metabolic Unit, C2:94, Karolinska University Hospital Huddinge, 141 86 Stockholm , Sweden"},{"name":"Medical Unit Endocrinology, C2:94, Karolinska University Hospital Huddinge , 141 86 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Parini","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet, Cardio Metabolic Unit, C2:94, Karolinska University Hospital Huddinge, 141 86 Stockholm , Sweden"},{"name":"Medical Unit Endocrinology, C2:94, Karolinska University Hospital Huddinge , 141 86 Stockholm , Sweden"},{"name":"Department of Laboratory Medicine, Cardio Metabolic Unit, Karolinska Institutet, Alfred Nobels All\u00e9 8, 141 52 Huddinge , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-6205","authenticated-orcid":false,"given":"Jonas","family":"Brinck","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Karolinska Institutet, Cardio Metabolic Unit, C2:94, Karolinska University Hospital Huddinge, 141 86 Stockholm , Sweden"},{"name":"Medical Unit Endocrinology, C2:94, Karolinska University Hospital Huddinge , 141 86 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2024043011303689800_oeae010-B1","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2024043011303689800_oeae010-B2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"2024043011303689800_oeae010-B3","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2024043011303689800_oeae010-B4","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","journal-title":"J Hepatol"},{"key":"2024043011303689800_oeae010-B5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"2024043011303689800_oeae010-B6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024043011303689800_oeae010-B7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024043011303689800_oeae010-B8","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/ATVBAHA.122.318445","article-title":"Genetic testing for hypertriglyceridemia in academic lipid clinics: implications for precision medicine\u2014brief report","volume":"42","author":"Deshotels","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024043011303689800_oeae010-B9","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1038\/s41467-019-11954-8","article-title":"Genetic architecture of human plasma lipidome and its link to cardiovascular disease","volume":"10","author":"Tabassum","year":"2019","journal-title":"Nat Commun"},{"key":"2024043011303689800_oeae010-B10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11883-021-00939-y","article-title":"The genetic basis of hypertriglyceridemia","volume":"23","author":"Carrasquilla","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2024043011303689800_oeae010-B11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2024043011303689800_oeae010-B12","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2024043011303689800_oeae010-B13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"key":"2024043011303689800_oeae010-B14","doi-asserted-by":"crossref","first-page":"e1009501","DOI":"10.1371\/journal.pgen.1009501","article-title":"ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease","volume":"17","author":"Helkkula","year":"2021","journal-title":"PLoS Genet"},{"key":"2024043011303689800_oeae010-B15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2024043011303689800_oeae010-B16","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024043011303689800_oeae010-B17","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2024043011303689800_oeae010-B18","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2024043011303689800_oeae010-B19","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2024043011303689800_oeae010-B20","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"2024043011303689800_oeae010-B21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"2024043011303689800_oeae010-B22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2024043011303689800_oeae010-B23","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","article-title":"The dawn of a new era of targeted lipid-lowering therapies","volume":"43","author":"Tokgozoglu","year":"2022","journal-title":"Eur Heart J"},{"key":"2024043011303689800_oeae010-B24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"2024043011303689800_oeae010-B25","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/eci.13841","article-title":"Volanesorsen to treat severe hypertriglyceridaemia: a pooled analysis of randomized controlled trials","volume":"52","author":"Calcaterra","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"2024043011303689800_oeae010-B26","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","article-title":"Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8","volume":"321","author":"Sylvers-Davie","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2024043011303689800_oeae010-B27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"key":"2024043011303689800_oeae010-B28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"2024043011303689800_oeae010-B29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/00365510410006324","article-title":"The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties","volume":"64","author":"Rustad","year":"2004","journal-title":"Scand J Clin Lab Invest"},{"key":"2024043011303689800_oeae010-B30","author":"Equalis"},{"key":"2024043011303689800_oeae010-B31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2024043011303689800_oeae010-B32","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/B978-0-323-29738-7.00037-X","volume-title":"Williams Textbook of Endocrinology","author":"Semenkovich","year":"2016","edition":"13th ed"},{"key":"2024043011303689800_oeae010-B33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","article-title":"Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia","volume":"19","author":"Bor\u00e9n","year":"2022","journal-title":"Nature reviews Cardiology"},{"key":"2024043011303689800_oeae010-B34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024043011303689800_oeae010-B35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"2024043011303689800_oeae010-B36","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"2024043011303689800_oeae010-B37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis\u2014from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2024043011303689800_oeae010-B38","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"2024043011303689800_oeae010-B39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2024043011303689800_oeae010-B40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bbalip.2011.09.021","article-title":"Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis","volume":"1821","author":"Schwartz","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2024043011303689800_oeae010-B41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/01.RES.0000258023.76515.a3","article-title":"Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha","volume":"100","author":"Ting","year":"2007","journal-title":"Circ Res"},{"key":"2024043011303689800_oeae010-B42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11883-009-0031-9","article-title":"Inflammation associated with the postprandial lipolysis of triglyceride-rich lipoproteins by lipoprotein lipase","volume":"11","author":"Higgins","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"2024043011303689800_oeae010-B43","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"2024043011303689800_oeae010-B44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MED.0000000000000715","article-title":"Hypertriglyceridemia: rationale, design and implementation of the Australian Hypertriglyceridemia Registry","volume":"29","author":"Pang","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2024043011303689800_oeae010-B45","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1080\/03007995.2023.2235153","article-title":"Observed consensus on research priorities for the hypertriglyceridemia patient registry","volume":"39","author":"Freedman","year":"2023","journal-title":"Curr Med Res Opin"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oeae010\/56719056\/oeae010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/4\/2\/oeae010\/57349234\/oeae010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/4\/2\/oeae010\/57349234\/oeae010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T11:31:39Z","timestamp":1714476699000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeae010\/7611400"}},"subtitle":[],"editor":[{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeae010","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,2,20]]},"article-number":"oeae010"}}